Key drivers for this market are: Growing Patient Population to Fuel Demand for Effective Therapeutics. Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

The Multiple Sclerosis Therapeutic Market is projected to reach $27.39 billion by 2033, exhibiting a CAGR of 5.9% from 2025 to 2033. Key drivers fueling market growth include the increasing prevalence of multiple sclerosis, rising healthcare expenditure, and the introduction of innovative therapies. The demand for immunosuppressants and injectable medications is expected to remain high due to their effectiveness in managing disease progression. The market is segmented based on drug class, route of administration, distribution channel, and region. North America held the largest market share in 2025, followed by Europe and Asia Pacific. The key players operating in this market include Teva Pharmaceutical Industries Ltd., Pfizer Inc., Biogen, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited., and Horizon Therapeutics plc. Recent developments include: In February 2024, Roche Pharma India announced the launch of Ocrevus for the treatment of MS. It is expected to cater to the requirements of patients suffering with MS in India. Ocrevus is one of its leading products and is available in more than 100 countries and in India it is approved for primary progressive & relapsing forms of MS. , In February 2024, Neuraxpharm Group announced the launch of BRIUMVI in Europe to treat adult patients suffering with relapsing MS. , In August 2023, the U.S. Food and Drug Administration (USFDA) approved Tyruko. Tyruko is the first biosimilar of Tysabri injection for treating adults suffering with relapsing form of MS. It is approved to treat relapsing-remitting disease, active secondary progressive disease and clinically isolated syndrome. .

The size and share of the market is categorized based on Type (Drug Treatment, Physical Therapy) and Application (Hospital, Clinic, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

In 2022, the value of multiple sclerosis (MS) treatments in Europe amounted to around 5.9 billion U.S. dollars. According to some projections, the market could reach some 8.7 billion dollars by 2028. Among world regions, North America represented by far the largest market for MS treatments.

The market size of the Stem Cell Therapy For Multiple Sclerosis Market is categorized based on Type (Intravenous, Intracerebroventricular) and Application (Relapsing-Remitting Multiple Sclerosis (RRMS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Progressive Relapsing Multiple Sclerosis (PRMS)) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This report provides insights into the market size and forecasts the value of the market, expressed in USD million, across these defined segments.

The size of the Multiple Sclerosis Drugs and Treatment market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.87% during the forecast period.Multiple Sclerosis is a central nervous system auto immune disease that affects the central nervous system, which involves the brain and spinal cord. In this disease, the immune system attacks the myelin sheath that protects nerve fibers, leading to inflammation and damage. This would therefore disrupt communication between the brain and the rest of the body, which can occur through a wide range of symptoms, such as impairment in vision, muscle weakness, fatigue, and cognitive problems.MS drugs and treatments control the progression of the disease and remove the symptoms of MS. Various categories of drugs have been designed that target specific areas of the disease. Some are categorized as DMTs, or disease-modifying therapies, where the action is immunosuppressive, thus reducing the severity and frequency of relapse attacks. The others include corticosteroids to treat acute attacks of the disease and reduce inflammation.Recently, major breakthroughs have occurred in treatment development for MS. More and more targeted and specific new oral drugs and infusion therapies that are more effective on the disease are being discovered. Other novel approaches include stem cell transplantation and gene therapy. Because of this, the market for MS drugs and treatment is constantly evolving as these are continuously researched and developed to improve patient outcomes and quality of life. Recent developments include: October 2023: Bristol Myers Squibb presented Zeposia's (ozanimod) data on long-term disease progression and cognition in patients with relapsing forms of multiple sclerosis (MS). 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP)., September 2023: Sandoz received the European Commission (EC) marketing authorization for biosimilar Tyruko (natalizumab) for multiple sclerosis. The US FDA approved the same product in August 2023.. Key drivers for this market are: Rising Cases of Multiple Sclerosis across the World, Growing Focus of Companies on Pipeline Products for MS. Potential restraints include: Side Effects Associated with the Medication, High Cost of the Drugs. Notable trends are: The Oral Route of Administration is Expected to Witness Rapid Growth in Over the Forecast Period.

The Relapsing Multiple Sclerosis Treatment market is expected to reach a value of USD XXX million in 2033, growing at a CAGR of XX% during the forecast period 2025-2033. The rising prevalence of multiple sclerosis and increasing awareness about treatment options are the key drivers of market growth. The market is segmented on the basis of application, type, and region. By application, the market is segmented into therapy, maintenance therapy, and others. By type, the market is segmented into disease-modifying therapies, symptomatic therapies, and others. By region, the market is segmented into North America, South America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to hold the largest market share during the forecast period, followed by Europe and Asia Pacific.

The size and share of the market is categorized based on Type (Intravenous, Intracerebroventricular) and Application (Relapsing-Remitting Multiple Sclerosis (RRMS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Progressive Relapsing Multiple Sclerosis (PRMS)) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

Snapshot img

Neurodegenerative Diseases Therapeutics Market Size 2024-2028

The neurodegenerative diseases therapeutics market size is forecast to increase by USD 21.29 billion at a CAGR of 8.51% between 2023 and 2028.

The market is experiencing significant growth due to the strong drug development pipeline and the increasing aging population. However, the lack of disease-modifying therapies poses a major challenge. To address this challenge, advancements in technology are being explored, such as the integration of virtual assistants and automation in healthcare. For instance, robotic vacuum cleaners and window cleaning robots are being used to assist in daily chores, freeing up time for caregivers. These devices employ advanced sensors and suction technology, including magnets and a two-step cleaning process, to ensure thorough cleaning of surfaces. Remote controllers enable users to operate these devices with ease, further enhancing their convenience. As smart homes become more prevalent, the integration of these technologies with healthcare systems is expected to revolutionize care for neurodegenerative disease patients.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Neurodegenerative diseases, such as Alzheimer's and Parkinson's, continue to pose significant challenges in healthcare. While there is ongoing research for effective therapeutics, the focus on improving the quality of life for patients has led to an increase in demand for assistive technologies. The residential sector, including suction mechanism sector with brushes and wipers, and the battery-powered sector, have seen growth in the automatic cleaning industry. Robotic vacuum cleaners with advanced sensors and compatibility for various floor types have gained popularity. Additionally, window cleaning robots with suction, magnets, and two-step cleaning processes have emerged. These robotic cleaners and floor cleaning robots offer remote control features, making them convenient for users.



Industrialization activities and building constructions have led to an increased need for cleaning robots in commercial settings. The automatic cleaning industry is expected to grow, driven by the increasing demand for efficient and effective cleaning solutions. Dirt and dust on glass surfaces can also be addressed with the help of advanced sensors and polishing technologies in window cleaning robots.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Indication

  Multiple sclerosis
  Alzheimers disease
  Parkinsons disease
  Huntingtons disease
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Indication Insights

The multiple sclerosis segment is estimated to witness significant growth during the forecast period.

The market, particularly in the segment for Multiple Sclerosis (MS), is witnessing significant growth due to the increasing prevalence of this disease. In the US alone, approximately 1 million people are affected by MS, while globally, around 2.9 million individuals are diagnosed with this condition. To cater to this growing population, key companies are actively investing in research and development of novel therapeutics. Advanced technologies, such as Artificial Intelligence (AI), the Internet of Things (IoT), micro-electromechanical systems, sensors, vision technologies, robotics innovation, and cleaning robots, are being leveraged to develop interoperable solutions for MS patients. These technologies enable the creation of smart speakers, visualization equipment, and low-cost cleaning robots, enhancing the quality of life for patients.

Furthermore, the commercial section of this market is expected to experience strong growth during the forecast period as these advanced technologies and innovative drugs, such as Tecfidra, Aubagio, Lemtrada, Gilenya, and Tysabri, come to market.

Get a glance at the market report of share of various segments Request Free Sample

The Multiple sclerosis segment was valued at USD 14.44 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

The market in North America holds the largest market share in 2023, driven by the presence of prominent players. Key products in this category include T

Snapshot img

Spasticity Treatment Market Size 2025-2029

The spasticity treatment market size is forecast to increase by USD 1.27 billion at a CAGR of 4.3% between 2024 and 2029.

The market is witnessing significant growth due to the increasing incidence of chronic diseases and health conditions that result in spasticity. This condition, characterized by involuntary muscle contractions, affects a large population, particularly the elderly and individuals with neurological disorders. A key trend driving market growth is the advent of neurostimulation devices, which provide effective relief from spasticity symptoms. However, the high cost associated with these treatments remains a significant challenge, limiting access for many patients. Overall, the market is expected to continue expanding as new technologies and treatment options emerge to address the unmet needs of this patient population.

What will be the Size of the Spasticity Treatment Market During the Forecast Period?

Request Free Sample

The market encompasses a range of advanced technologies and therapies aimed at managing abnormal posture, overactive reflexes, and involuntary muscle spasms resulting from various neurological conditions. These conditions, including brain injury, cerebral palsy, and chronic neuro-musculoskeletal illnesses, can lead to increased muscle tone, stiffness, clonus, and other symptoms. Despite the availability of physiotherapy, stimulatory devices, drugs, and physiotherapy centers, the market faces challenges such as inadequate reimbursement, lack of awareness, and limited access to skilled professionals. New developments In the product pipeline analysis, including novel therapeutics and healthcare expenditure, offer potential revenue pockets for market participants. Rehabilitation nurses, recreational therapists, and healthcare facilities, including hospital pharmacies, play crucial roles in the delivery of spasticity treatment.
The growing population of children with neurological disorders and the prevalence of accidents, assaults, and other causes of spasticity further expand the market's reach. Adverse effects and product approval processes pose regulatory hurdles, while the need for continuous care and the complex nature of spasticity management present ongoing challenges.

How is this Spasticity Treatment Industry segmented and which is the largest segment?

The spasticity treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Drug therapy
  Physical therapy
  Surgical treatment


End-user

  Hospitals
  Ambulatory surgical centers
  Home care settings
  Specialty clinics
  Diagnostic centers


Indication

  Cerebral palsy
  Multiple sclerosis
  Traumatic brain injury
  Others


Route Of Administration

  Oral
  Parenteral


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Type Insights

The drug therapy segment is estimated to witness significant growth during the forecast period.

Spasticity, a muscle control disorder characterized by muscle stiffness, tightness, and increased tone, affects millions of patients with neurological conditions such as spinal cord injury, stroke, and cerebral palsy. Treatment options include pharmaceutical interventions like antispasmodic agents such as baclofen and muscle relaxants, as well as non-invasive therapies such as physical therapy exercises, speech therapy, and assistive devices. Movement disorders specialists, neurologists, orthopedic interventions, and rehabilitation centers provide diagnosis and treatment. Clinical trials are ongoing to explore new innovations, including botulinum toxin injections and reimbursement policies. Insurance coverage and patient advocacy play crucial roles in ensuring equitable access to care.

Get a glance at the market report of share of various segments Request Free Sample

The drug therapy segment was valued at USD 2.97 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 36% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American region dominates The market due to the high prevalence of neurological disorders, such as multiple sclerosis, which is a leading cause of spasticity. According to the National Center for Complementary and Integrative Health, multiple sclerosis affects approximately 400,000 Americans, m

The Neurodegenerative Diseases Therapeutics market is experiencing robust growth, projected to reach $42.21 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 8.51% from 2025 to 2033. This significant expansion is fueled by several key factors. The aging global population is a major driver, leading to an increased prevalence of neurodegenerative diseases like Alzheimer's, Parkinson's, multiple sclerosis, and Huntington's disease. Furthermore, ongoing research and development efforts are resulting in the introduction of innovative therapies, including disease-modifying drugs and advanced diagnostics, which are improving treatment outcomes and patient quality of life. Increased investment in research and development by pharmaceutical companies, coupled with growing government funding for clinical trials and disease awareness campaigns, further contributes to market growth. While challenges remain, such as the high cost of treatment and the complexities involved in developing effective therapies for these complex diseases, the market's future trajectory remains positive. Market segmentation reveals significant opportunities within specific disease areas. Alzheimer's disease, due to its high prevalence and substantial unmet medical needs, represents a considerable segment of the market. Parkinson's disease and multiple sclerosis also contribute substantially to market value, with ongoing research focused on improving treatment efficacy and addressing disease progression. The "Others" segment, encompassing rarer neurodegenerative diseases, represents a niche but potentially lucrative area for specialized therapies and future growth. Geographical analysis shows a strong concentration of market share in North America and Europe, driven by advanced healthcare infrastructure, high healthcare expenditure, and a larger aging population in these regions. However, emerging markets in Asia are demonstrating significant growth potential, presenting expanding opportunities for pharmaceutical companies in the years to come. Competitive analysis indicates a landscape of established players and emerging biotech companies vying for market share through innovative therapies, strategic partnerships, and aggressive marketing efforts.

Snapshot img

Neurologic Disorders Therapeutics Market Size 2024-2028

The neurologic disorders therapeutics market size is forecast to increase by USD 27.2 billion at a CAGR of 4.49% between 2023 and 2028.

Neurologic disorders, such as Parkinson's disease, Alzheimer's disease, and epilepsy, continue to pose significant challenges for the healthcare industry. The market is experiencing strong growth, driven by several key trends. The approval of novel drugs, including gene therapies and monoclonal antibodies, is revolutionizing the treatment landscape. Additionally, the advent of regenerative medicines, including stem cell therapy and gene editing techniques, offers promising solutions for debilitating neurological conditions. Furthermore, the increasing adoption of neurostimulation devices, such as deep brain stimulators and transcranial magnetic stimulators, is transforming the way neurological disorders are managed. These trends are expected to continue shaping the market In the coming years. Despite these advancements, challenges remain, including high treatment costs, limited access to specialized care, and the need for long-term management strategies. Addressing these challenges will require collaborative efforts from industry, academia, and regulatory bodies to ensure affordable and effective treatments for neurological disorders.

What will be the Size of the Neurologic Disorders Therapeutics Market During the Forecast Period?

Request Free Sample

The market encompasses diagnostics and pharmaceutical treatments for various Central Nervous System (CNS) conditions, including Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and stroke. The global market for neurologic disorders therapeutics is experiencing significant growth due to the increasing burden of disease and the demand for effective therapeutics. According to Deloitte Insights, global spending on mental health disorders, which include neuropsychiatric conditions, is projected to reach USD1 trillion by 2020. The market dynamics are influenced by factors such as patent expiration, leading to the availability of generic products, and the development of new, innovative treatments. Neurological conditions, including neurodegenerative diseases like Alzheimer's and Parkinson's, and neuropsychiatric disorders, such as anxiety and depression, continue to pose a significant challenge to healthcare systems worldwide.
Furthermore, the neurology market also includes treatments for conditions like epilepsy, multiple sclerosis, and stroke, which affect millions of people globally. Effective therapeutics for these conditions are in high demand, as they can significantly improve patients' quality of life and reduce the burden on healthcare systems. The market for neurologic disorders therapeutics is also influenced by the development of new treatments for cardiovascular diseases, cancer, and other conditions that affect the neurons and glial cells In the CNS. Pharmaceutical companies are investing heavily in research and development to bring new, innovative treatments to market, with a focus on addressing the unmet needs of patients with neurological and neuropsychiatric conditions.

How is this Neurologic Disorders Therapeutics Industry segmented and which is the largest segment?

The neurologic disorders therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Application

  CNS
  PNS


Geography

  North America

    Canada
    US


  Europe

    UK


  Asia

    China
    India


  Rest of World (ROW)

By Application Insights

The CNS segment is estimated to witness significant growth during the forecast period.

Central nervous system (CNS) disorders encompass conditions affecting the brain and spinal cord. These disorders can be categorized into functional and degenerative types. Functional disorders, which are more prevalent, include indications such as epilepsy, migraine, dizziness, insomnia, depression, anxiety, bipolar disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), and Obsessive-Compulsive Disorder (OCD). Degenerative disorders, also known as neurodegenerative diseases, involve the decline of neurons In the brain. Neurological disorders, including CNS conditions, pose a significant burden of disease and affect millions worldwide. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are particularly challenging due to their complex nature and limited effective therapeutics. Pharmaceutical companies invest heavily in research and development (R&D) to create effective therapeutics for these conditions.

Get a glance at the Neurologic Disorders Therapeutics Industry report of share of various segments Request Free Sample

The CNS segment wa

The size and share of the market is categorized based on Type (COG-133, GZ-402668, Inebilizumab, VCE-0032, Others) and Application (Clinic, Hopital, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The global autoimmune and inflammatory immunomodulators market is experiencing robust growth, driven by rising prevalence of autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. An aging population, increased awareness of these conditions, and advancements in immunomodulatory therapies are key contributors to this expansion. The market's substantial size, estimated at $XX billion in 2025 (assuming a reasonable market size based on similar pharmaceutical markets), is projected to exhibit a healthy Compound Annual Growth Rate (CAGR) of XX% throughout the forecast period (2025-2033). This growth is further fueled by ongoing research and development efforts leading to the introduction of novel, more effective, and targeted therapies with improved safety profiles. Competition among major pharmaceutical players such as AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, and Pfizer is intense, driving innovation and potentially lowering treatment costs. However, the market faces challenges including high drug prices, potential side effects of immunomodulators, and varying regulatory approvals across different regions. Segmentation by type (e.g., biologics, small molecules) and application (e.g., rheumatoid arthritis, multiple sclerosis) reveals varying growth rates, with biologics generally commanding a larger market share due to their efficacy. Geographical analysis suggests that North America and Europe currently dominate the market due to higher healthcare expenditure and advanced healthcare infrastructure. However, emerging markets in Asia-Pacific are poised for significant growth in the coming years due to rising disease prevalence and increasing healthcare investments. The market's future trajectory depends on several factors. Continued R&D investments will be critical in developing next-generation immunomodulators with enhanced efficacy and reduced adverse effects. Government initiatives aimed at improving healthcare access and affordability in developing nations will play a significant role in expanding market penetration. Furthermore, the evolving understanding of autoimmune and inflammatory diseases and the development of personalized medicine approaches will contribute to refining treatment strategies and further enhancing market growth. Competitive landscapes will continue to shift as pharmaceutical companies develop new products and explore strategic partnerships. The market’s success will also depend on the development of sustainable and cost-effective treatment strategies that address the long-term needs of patients while managing the financial burdens associated with these therapies.

The global spasticity treatment market, valued at $5.24 billion in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033. This expansion is driven by several key factors. The rising prevalence of neurological disorders like cerebral palsy, multiple sclerosis, and stroke, leading to increased spasticity cases, is a primary driver. Technological advancements in minimally invasive surgical techniques, drug therapies, and rehabilitation programs are also significantly contributing to market growth. Furthermore, an aging global population, coupled with improved healthcare infrastructure and increased awareness regarding spasticity management, fuels market expansion. The market's segmentation reveals a diverse landscape, with drug therapy currently holding the largest segment share, followed by physical therapy and surgical treatment. Hospitals are the dominant end-users, but the home care setting is witnessing substantial growth, driven by increasing patient preference for convenient and cost-effective treatment options. Geographically, North America currently commands a significant market share, owing to advanced healthcare infrastructure and high prevalence rates. However, Asia-Pacific is anticipated to demonstrate faster growth due to expanding healthcare facilities and rising disposable incomes in developing economies within this region. The competitive landscape is characterized by a mix of established pharmaceutical and medical device companies alongside specialized clinics and research institutions. Major players are actively engaged in research and development, aiming to introduce innovative therapies and technologies. Strategic collaborations, mergers, and acquisitions are frequent occurrences, reflecting the intense competition and significant market potential. The market, however, faces certain restraints. High treatment costs, particularly for advanced surgical procedures and novel drug therapies, can limit accessibility, especially in low- and middle-income countries. Furthermore, the variability in spasticity symptoms and the lack of universally effective treatments pose challenges. However, ongoing research efforts focused on personalized medicine and the development of more targeted therapies are expected to mitigate these limitations and further fuel market expansion in the coming years.

The Anti-Inflammatory Drugs Market Report is Segmented by Treatment (Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Asthma, Tendonitis, and Other Treatments), Drug Class (Anti-Inflammatory Biologics, Non-Steroidal Anti Inflammatory Drugs (NSAIDs), Corticosteroids, Immune-Selective Anti-Inflammatory Derivatives (ImSAID), and Other Drug Classes), Sales Channel (Prescription and Over the Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts for all the Above Segments in Value (USD).

Snapshot img

Gastrointestinal Diseases Therapeutics Market Size 2024-2028

The gastrointestinal diseases therapeutics market size is forecast to increase by USD 18.53 billion at a CAGR of 6.81% between 2023 and 2028.

The market is witnessing significant growth due to the increasing incidence of gastrointestinal disorders such as Inflammatory Bowel Disease (IBD) and Gastroesophageal Reflux Disease (GERD). The availability of nutritional therapies is another growth factor, as these therapies offer an alternative to traditional pharmaceutical treatments. However, the high cost of gastrointestinal therapeutics remains a challenge for the market. Stool testing, a diagnostic tool used In the detection and monitoring of gastrointestinal diseases, is experiencing increased demand due to its accuracy and non-invasive nature. The Simethicone market is also growing due to its effectiveness in treating symptoms of GERD, such as bloating and burping.
Overall, the market is expected to continue its growth trajectory, driven by the rising prevalence of gastrointestinal diseases and the development of new and innovative therapeutic solutions.

What will be the Size of the Gastrointestinal Diseases Therapeutics Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of chronic conditions, including gastroesophageal reflux disease, inflammatory bowel diseases such as Crohn's and ulcerative colitis, irritable bowel syndrome, gastrointestinal cancers, and various autoimmune diseases like type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, psoriasis, and scleroderma. This market continues to expand due to the increasing global prevalence of these conditions and the unmet medical needs for effective and well-tolerated treatment options. Novel therapies, including targeted drugs, are gaining significant attention for their potential to revolutionize the treatment landscape. The market is characterized by ongoing research and development efforts, regulatory approvals, and collaborations between industry players and academic institutions to bring innovative solutions to market. The overall size of the market is substantial and growing, driven by the increasing burden of chronic gastrointestinal diseases and the ongoing quest for improved patient outcomes.

How is this Gastrointestinal Diseases Therapeutics Industry segmented?

The gastrointestinal diseases therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Drug Class

  Anti-inflammatory and immunosuppressors
  Acid neutralizers
  Others


Type

  Branded
  Generics


Geography

  North America

    US


  Asia

    China
    Japan


  Europe

    Germany
    France


  Rest of World (ROW)

By Drug Class Insights

The anti-inflammatory and immunosuppressors segment is estimated to witness significant growth during the forecast period.

The market encompasses a range of treatments for conditions such as gastroesophageal reflux disease, inflammatory bowel disease (IBD), irritable bowel syndrome, gastrointestinal cancers, autoimmune diseases, Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and scleroderma. The market is driven by the increasing prevalence of chronic digestive diseases, clinical trials, and the introduction of novel therapies and targeted drugs. Biologics, including Inflectra, Remicade, Renflexis, Tysabri, Ustekinumab, Risankizumab, TNF blockers, and Zeposia, are playing a significant role In the market's growth. Patent expirations and the availability of biosimilars, such as Linzess, Humira, Adalimumab, Certolizumab, Infliximab, and Natalizumab, are also impacting the market dynamics.

Over-the-counter (OTC) drugs, including anti-emetics and laxative preparations, are also part of the market landscape. The market is segmented into injectable and non-injectable drugs, with the injectable segment holding a larger share due to the effectiveness of biologics. Telemedicine and online pharmacies are emerging channels for the distribution of gastrointestinal drugs.

Get a glance at the market report of share of various segments Request Free Sample

The Anti-inflammatory and immunosuppressors segment was valued at USD 21.68 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The market in North America is experiencing significant growth due to the